Mr. Gordon currently serves as President and CEO of Katmai Pharmaceuticals, a neuro-oncology-focused biotech founded by leading chemistry, drug development, and clinical researchers at UCLA. During his career, Mr. Gordon played pivotal roles in the startup and growth of four biopharmaceutical companies along with one of the leading life science industry organizations, BIOCOM California. Throughout his career he served in executive management positions, including CFO and VP Business Development, responsible for funding, launching, building, partnering, acquiring and exiting both VC-funded and public biotechs. These include start-up ventures that established early foundational technologies in the fields of human gene therapy, kinase targeted small molecule drugs, protein degraders, stem cell regenerative and biomaterial treatments, and oncogene-targeted therapeutics. He has executed a large and diverse range of equity, debt, in/out licensing, R&D partnering, and M&A transactions across major international pharmaceutical markets including the U.S., Europe, and Japan. In addition to his private sector work, Mr. Gordon co-founded and currently serves as board chairman for one of the largest life science strategic procurement organizations worldwide, Core at BIOCOM California, serving over 1,700 member companies at over 3,500 sites and generating over $800MM annual group purchasing volume.
